News & Updates on our SARS-CoV-2 Research

Since spring 2020, scientists of the Vienna BioCenter have continuously made important contributions to the struggle to control the pandemic. Key developments include self-sampling protocols via gargling, monitoring pipelines, innovative testing methods such as RT-LAMP, mutant strain monitoring via SARSeq, or the development of vaccines and COVID-19 therapeutics.

Below, you find an overview on relevant news items from this challenging but yielding period. This overview list will be continued.

Valneva Completes Phase 3 Trial Recruitment for its Inactivated COVID-19 Vaccine Candidate

3 June 2021. Valneva announced that it has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. 

Harnessing Next Generation Sequencing to detect SARS-CoV-2 and prepare for the next pandemic

25 May 2021. Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.

Valneva to Participate in the World’s First COVID-19 Vaccine Booster Trial in the UK

19 May 2021. Valneva announced it will participate in a UK government-funded clinical trial looking at different COVID-19 ‘booster’ vaccines.

CEBINA reports potency of azelastine against emerging dominant variants of SARS-CoV-2 in laboratory testing

04 May 2021. CEBINA announced that azelastine is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus.

Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001

21 April 2021. Valneva announced it has initiated a pivotal Phase 3 clinical trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Valneva COVID-19 Vaccine Candidate: Positive Phase 1/2 Data

06 APRIL 2021. Valneva announced positive data for Part A of the Phase 1/2 clinical trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.


Valneva Announces UK Exercise of COVID-19 Vaccine Option

01 FEBRUARY 2021. Valneva reported that the UK Government has exercised its option to order 40 million doses of its inactivated, adjuvanted COVID-19 vaccine candidate for supply in 2022.


Valneva Commences COVID-19 Vaccine Manufacturing

28 JANUARY 2021. Valneva announced it has commenced production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in order to optimize the timeline for potential deliveries of the vaccine.


Valneva in Advanced Discussions with European Commission

12 JANUARY 2021. Valneva announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.


Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

16 DECEMBER 2020. Valneva announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.


Pilot project in nursing homes for Covid-19 monitoring

07 DECEMBER 2020. In a pilot project, researchers of the "Vienna Covid-19 Detection Initiative" (VCDI) at the Vienna BioCenter, Caritas of the Archdiocese of Vienna and the association Novid20 show how institutions can continuously screen larger groups of people.


PCR alternative: RT-LAMP, a new SARS-CoV-2 test "Made in Vienna"

21 OCTOBER 2020. Scientists from the Vienna BioCenter developed a new SARS-CoV-2 detection method: by rather simple means, their RT-LAMP test is cheaper than PCR testing and achieves results with comparable sensitivity and specificity.


Testing technology of future: 36,000 samples per night

05 NOVEMBER 2020. A new method developed by researchers of the Vienna BioCenter, SARSeq, will allow testing of thousands of samples for SARS-CoV-2 and other pathogens in just 15 to 24 hours.


CEBINA shows potency of azelastine as anti-COVID-19 approach

17 SEPTEMBER 2020. CEBINA shows positive results in its collaborative COVID-19 drug repurposing project, demonstrating that a common allergy nasal spray has potent efficacy against SARS-CoV-2.


Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

14 SEPTEMBER 2020. Valneva announced a vaccine partnership with the UK government for its inactivated COVID-19 vaccine, VLA2001.


Researchers develop a "quick and easy" Covid-19 test

24 JUNE 2020. Scientists from the Vienna BioCenter have pushed SARS-CoV-2 detection to a new level. Their approach is as sensitive and robust, yet cheaper, simpler and faster to implement than conventional tests.


Funding for CEBINA extended spectrum Coronavirus vaccine

04 JUNE 2020. CEBINA announced that it has received seed funding for its extended spectrum Coronavirus vaccine project, which is part of CEBINA’s broad-scale efforts offering short-, mid- and longer-term solutions to fight the COVID-19 pandemic.


Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19

22 APRIL 2020. Valneva and Dynavax Technologies Corporation announced their collaboration to initiate a vaccine program for the current coronavirus, COVID-19.


CEBINA joins the global efforts to fight COVID-19

17 APRIL 2020. The Austrian biotech incubator and accelerator CEBINA GmbH announces the initiation of several collaborative projects that address the global health crisis caused by the pandemic spread of the SARS-CoV-2 virus.


Vienna COVID-19 Diagnostics Initiative

03 APRIL 2020. The Vienna COVID-19 Diagnostics Initiative (VCDI) is a collaborative effort involving 20 scientific institutions across Vienna. The initiative has repurposed existing infrastructure, resources, and manpower to build a new diagnostics pipeline....


Fighting SARS-CoV-2 in human blood vessel organoids

03 APRIL 2020. A team of international scientists with participation of IMBA produced groundbreaking results in blocking viral infections in human organoids by inhibiting interactions with the SARS-CoV-2 receptor ACE2.